Evidence map›Paper›PMID 41351306›Full record

ReviewNanomedicine (London, England)2026

Emerging nanotechnology-enabled siRNA oral delivery platforms.

Angelea Maestas-Olguin, Maya M Dawson, Emily Rhoades Clark, Olivia L Lanier

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Angelea Maestas-OlguinDepartment of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Maya M DawsonDepartment of Biomedical Engineering, University of New Mexico, Albuquerque, NM, USA.
Emily Rhoades ClarkDepartment of Biomedical Engineering, University of New Mexico, Albuquerque, NM, USA.
Olivia L LanierDepartment of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.

Funding

FAIR Data Competency and Machine Learning Readiness for Biomedical ScientistsK12GM088021 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI REBECCA S. HARTLEY, Diane Lidke · 2009 to 2026
$16.4M
Redefining Nanomedicine Beyond One-Size-Fits-All: Uncovering Mechanisms of Sex Differences and Female Life Stages in Drug DeliveryR35GM160475 · NIGMS · UNIVERSITY OF NEW MEXICO · PI LANIER, OLIVIA LAUREN · 2025 to 2025
$1.8M
NIGMS NIH HHS K12 GM088021NIGMS NIH HHS R35 GM160475UNM Comprehensive Cancer Center American Cancer Society
6 · The paper itself

Abstract

Utilization of endogenous RNA interference (RNAi) mechanisms via delivery of exogeneous small interfering RNA (siRNA) molecules offers a transformative approach to treatment of disease by enabling sequence specific silencing of mutated gene expression. Nanotechnology-based platforms have enabled delivery of siRNA and have already been clinically validated for intravenous (IV) infusion administration (e.g patisiran). Oral administration of siRNA remains an unmet challenge due to formidable biological barriers in the gastrointestinal (GI) tract. Nanotechnology-enabled strategies for oral siRNA delivery have emerged as a powerful solution to overcoming these biological barriers for effective gene silencing. This review provides a comprehensive overview of GI barriers for siRNA delivery as well as highlights recent advances in nanoparticle platforms for oral siRNA delivery. In addition, this review explores translational considerations and highlights the potential of oral siRNA nanomedicines to reduce dependence on invasive parenteral delivery and costly monoclonal antibody therapies. Together, these advances outline a promising path toward clinically viable, patient-friendly siRNA therapeutics delivered orally. Literature for this review was identified through database searches [University of New Mexico University Libraries, Web of Science, Google Scholar, and PubMed databases April 2025-November 2025] as it related to the oral delivery of nanoparticles, siRNA-loaded nanoparticles, gene therapy, and related nanomedicine delivery strategies.

Indexed as

NanotechnologyRNA, Small InterferingAdministration, OralAnimalsDrug Delivery SystemsGastrointestinal TractGene SilencingGene Transfer TechniquesHumansNanomedicineNanoparticlesRNA InterferenceRNA, Small Interferinggene silencingGI tract biological barriersnanoparticlesoral deliverysiRNA

Identifiers

PMID41351306
PMCPMC12867379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.